New markers in serum for lymphocyte activation for predicting allograft rejection. Neopterin and soluble interleukin-2 receptor.
Investigations have been reported on the use of neopterin and soluble interleukin-2 receptors as rejection markers. Each of these analytes is available as part of an easy-to-perform analytic method. Each is available in a diagnostic kit that is accurate, precise, and sensitive enough to provide good clinical information. Both of these materials have a significant relationship with the cell-mediated immune response, particularly at the level of T-cell activation. Neopterin does increase significantly in cases of transplant rejection but shows greater response to viral infection. Soluble interleukin-2 receptors increase during periods of transplant rejection but also respond during T-cell activation brought on by bacterial or viral infection. The use of these markers is best described for kidney transplants and less well documented for liver and heart transplants.
Carlson
I H
IH
Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison.
D015415:Biomarkers / Q000097:blood*; D001708:Biopterins / Q000031:analogs & derivatives* / Q000097:blood; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008213:Lymphocyte Activation; D019798:Neopterin; D015375:Receptors, Interleukin-2 / Q000032:analysis*
D015415:Biomarkers; D015375:Receptors, Interleukin-2; D001708:Biopterins; D019798:Neopterin